HRP20151438T1 - Sastavi stabilnih tiakumicina - Google Patents
Sastavi stabilnih tiakumicina Download PDFInfo
- Publication number
- HRP20151438T1 HRP20151438T1 HRP20151438TT HRP20151438T HRP20151438T1 HR P20151438 T1 HRP20151438 T1 HR P20151438T1 HR P20151438T T HRP20151438T T HR P20151438TT HR P20151438 T HRP20151438 T HR P20151438T HR P20151438 T1 HRP20151438 T1 HR P20151438T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- pharmaceutical composition
- diarrhea
- enterocolitis
- gallate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 14
- 229930187202 Tiacumicin Natural products 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010012735 Diarrhoea Diseases 0.000 claims 4
- 208000010227 enterocolitis Diseases 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 3
- 241000193163 Clostridioides difficile Species 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 3
- 239000007909 solid dosage form Substances 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 241001112695 Clostridiales Species 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 206010012742 Diarrhoea infectious Diseases 0.000 claims 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 239000004262 Ethyl gallate Substances 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 235000010386 dodecyl gallate Nutrition 0.000 claims 1
- 239000000555 dodecyl gallate Substances 0.000 claims 1
- 229940080643 dodecyl gallate Drugs 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 235000019277 ethyl gallate Nutrition 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229960004592 isopropanol Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229940098895 maleic acid Drugs 0.000 claims 1
- 235000010387 octyl gallate Nutrition 0.000 claims 1
- 239000000574 octyl gallate Substances 0.000 claims 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Claims (13)
1. Farmaceutski sastav sadrži terapijski učinkovitu količinu tvari formule:
[image]
stabilizirajuću količinu jednog ili više antioksidanasa odabranih iz grupe koja se sastoji od butiliranog hidroksianisola, butiliranog hidroksitoluena, askorbinske kiseline, askorbil palmitata, propil galata, dodecil galata, etil galata, oktil galata, alfa tokoferola, natrijevog askorbata, natrijevog metabisulfita, fumarinske kiseline i maleinske kiseline, i opcionalno jednog ili više farmaceutski prihvatljivih ekscipijenasa odabranih iz grupe koja se sastoji od mikrokristalinične celuloze, škroba, hidroksipropilceluloze, natrijevog škrobnog glikolata, izopropilnog alkohola, magnezijevog stearata i njihovih kombinacija.
2. Sastav iz patentnog zahtjeva 1, pri čemu je farmaceutski sastav sadržajno stabilan u prisutnosti vlage.
3. Sastav iz patentnog zahtjeva 1, pri čemu je farmaceutski sastav sadržajno stabilan u prisutnosti topline.
4. Sastav iz patentnog zahtjeva 1, pri čemu je stabilizirajuća količina jednog ili više antioksidanasa od oko 0.001% do oko 50% ukupne težine navedenog sastava.
5. Sastav iz patentnog zahtjeva 1, pri čemu je jedan ili više antioksidanasa butilirani hidroksitoluen.
6. Sastav iz patentnog zahtjeva 1, pri čemu se sastav primjenjuje oralno.
7. Sastav iz patentnog zahtjeva 1, pri čemu je sastav u čvrstom obliku doziranja.
8. Sastav iz patentnog zahtjeva 7, pri čemu je čvrsti oblik doziranja tableta.
9. Sastav iz patentnog zahtjeva 7, pri čemu je čvrsti oblik doziranja razdijeljen u jedinično pakiranje doziranja.
10. Farmaceutski sastav iz patentnog zahtjeva 1 za uporabu u liječenju ili sprječavanju bolesti, infekcije i/ili drugih stanja povezanih s uporabom antibiotika, kemoterapija za karcinome, ili antivirusnih terapija kod subjekta.
11. Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 10, pri čemu je bolest, infekcija i/ili drugo stanje odabrano između sljedećeg: dijareje povezane s C. difficile (CDAD), kolitisa, pseudomembranoznog kolitisa, dijareje povezane s antibioticima i infekcijama uzrokovanim C. difficile, C. perfringens, Staphylococcus species, ili Enterococcus, klostridijskog enterokolitisa, neonatalne dijareje, enterokolitisa povezanog s antibioticima, sporadičnog enterokolitisa, nozokomijalnog enterokolitisa, membranoznog kolitisa, infektivne dijareje i sindroma iritabilnog crijeva.
12. Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 11, pri čemu je bolest, infekcija i/ili drugo stanje dijareja povezana s C. difficile (CDAD).
13. Farmaceutski sastav iz patentnog zahtjeva 1, pri čemu sastav sadrži terapijski aktivnu količinu tvari formule:
[image]
butiliranog hidroksitoluena u količini od oko 0.001% do oko 50% ukupne težine navedenog sastava i opcionalno jednog ili više od mikrokristalinične celuloze, škroba, hidroksipropilceluloze, natrijevog škrobnog glikolata i magnezijevog stearata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88113707P | 2007-01-19 | 2007-01-19 | |
| EP08724557.7A EP2121716B1 (en) | 2007-01-19 | 2008-01-17 | Compositions of stable tiacumicins |
| PCT/US2008/000591 WO2008091518A1 (en) | 2007-01-19 | 2008-01-17 | Compositions of stable tiacumicins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151438T1 true HRP20151438T1 (hr) | 2016-01-29 |
Family
ID=39641896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151438TT HRP20151438T1 (hr) | 2007-01-19 | 2015-12-30 | Sastavi stabilnih tiakumicina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20080176927A1 (hr) |
| EP (1) | EP2121716B1 (hr) |
| JP (2) | JP5635266B2 (hr) |
| KR (1) | KR101491729B1 (hr) |
| CN (2) | CN102015747A (hr) |
| BR (1) | BRPI0806713A8 (hr) |
| CA (1) | CA2676003C (hr) |
| CY (1) | CY1117237T1 (hr) |
| DK (1) | DK2121716T3 (hr) |
| ES (1) | ES2560669T3 (hr) |
| HR (1) | HRP20151438T1 (hr) |
| HU (1) | HUE028671T2 (hr) |
| IL (1) | IL199941A (hr) |
| MX (1) | MX2009007784A (hr) |
| NZ (1) | NZ578493A (hr) |
| PL (1) | PL2121716T3 (hr) |
| PT (1) | PT2121716E (hr) |
| RU (1) | RU2484829C2 (hr) |
| SI (1) | SI2121716T1 (hr) |
| TW (1) | TWI474820B (hr) |
| WO (1) | WO2008091518A1 (hr) |
| ZA (1) | ZA200905134B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906489B2 (en) | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7378508B2 (en) | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| TWI523654B (zh) | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
| BR112012029259A8 (pt) * | 2010-05-18 | 2021-03-23 | Optimer Pharmaceuticals Inc | tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos |
| CA2799531A1 (en) * | 2010-05-18 | 2011-11-24 | Optimer Pharmaceuticals, Inc. | Treating recurring clostridium difficile infection using fidaxomicin |
| CN103124498A (zh) * | 2010-06-02 | 2013-05-29 | 扩散药品有限公司 | 双极性反式类胡萝卜素的口服制剂 |
| MX2013009033A (es) * | 2011-02-04 | 2013-09-06 | Optimer Pharmaceuticals Inc | Tratamiento de infecciones bacterianas. |
| ITMI20120560A1 (it) | 2012-04-05 | 2013-10-06 | Olon Spa | Procedimento per la purificazione della tiacumicina b |
| JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| US20150141356A1 (en) * | 2013-11-15 | 2015-05-21 | Optimer Pharmaceuticals, Inc. | Treatment of Clostridium Difficile Infection in High Risk Patients |
| WO2015127955A1 (en) | 2014-02-25 | 2015-09-03 | Olon S.P.A. | A new polymorph of tiacumicin b and process for preparation thereof |
| DK3139932T3 (en) * | 2014-05-09 | 2018-11-12 | Astellas Pharma Europe Ltd | The treatment regimen for thiacumicin compound |
| CN110037992B (zh) * | 2019-05-28 | 2021-05-28 | 杭州华东医药集团新药研究院有限公司 | 一种稳定的非达霉素组合物 |
| CN112353774B (zh) * | 2020-11-17 | 2022-08-23 | 浙江汇能生物股份有限公司 | 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05192094A (ja) * | 1991-09-03 | 1993-08-03 | Takeda Chem Ind Ltd | 造粒組成物 |
| US5583115A (en) * | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| AU2001211213A1 (en) * | 2000-10-20 | 2002-04-29 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| US20030099699A1 (en) * | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| ES2527052T3 (es) * | 2002-07-29 | 2015-01-20 | Optimer Pharmaceuticals, Inc. | Producción de tiacumicina |
| US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| WO2004056337A2 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| MX2007009196A (es) * | 2005-01-31 | 2009-02-25 | Optimer Pharmaceuticals Inc | Compuestos macrocilicos de 18 miembros y analogos de los mismos. |
-
2008
- 2008-01-14 US US12/008,751 patent/US20080176927A1/en not_active Abandoned
- 2008-01-17 CA CA2676003A patent/CA2676003C/en active Active
- 2008-01-17 CN CN2008800078761A patent/CN102015747A/zh active Pending
- 2008-01-17 CN CN201510502516.0A patent/CN105169396A/zh active Pending
- 2008-01-17 DK DK08724557.7T patent/DK2121716T3/en active
- 2008-01-17 MX MX2009007784A patent/MX2009007784A/es active IP Right Grant
- 2008-01-17 PT PT87245577T patent/PT2121716E/pt unknown
- 2008-01-17 KR KR1020097017319A patent/KR101491729B1/ko active IP Right Grant
- 2008-01-17 NZ NZ578493A patent/NZ578493A/en unknown
- 2008-01-17 SI SI200831576T patent/SI2121716T1/sl unknown
- 2008-01-17 BR BRPI0806713A patent/BRPI0806713A8/pt not_active Application Discontinuation
- 2008-01-17 EP EP08724557.7A patent/EP2121716B1/en active Active
- 2008-01-17 RU RU2009128612/15A patent/RU2484829C2/ru active
- 2008-01-17 WO PCT/US2008/000591 patent/WO2008091518A1/en active Search and Examination
- 2008-01-17 ES ES08724557.7T patent/ES2560669T3/es active Active
- 2008-01-17 JP JP2009546419A patent/JP5635266B2/ja active Active
- 2008-01-17 HU HUE08724557A patent/HUE028671T2/en unknown
- 2008-01-17 PL PL08724557T patent/PL2121716T3/pl unknown
- 2008-03-10 TW TW097108321A patent/TWI474820B/zh active
-
2009
- 2009-07-19 IL IL199941A patent/IL199941A/en active IP Right Grant
- 2009-07-22 ZA ZA2009/05134A patent/ZA200905134B/en unknown
-
2012
- 2012-03-09 US US13/416,768 patent/US20130065844A1/en not_active Abandoned
-
2014
- 2014-06-24 JP JP2014129106A patent/JP5995331B2/ja active Active
-
2015
- 2015-12-30 HR HRP20151438TT patent/HRP20151438T1/hr unknown
-
2016
- 2016-03-01 CY CY20161100177T patent/CY1117237T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151438T1 (hr) | Sastavi stabilnih tiakumicina | |
| JP2010516677A5 (hr) | ||
| KR20140075754A (ko) | 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제 | |
| CN102895208A (zh) | 包衣片制剂和方法 | |
| HRP20161231T1 (hr) | Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore | |
| HRP20151095T1 (hr) | Farmaceutski pripravci koji sadrže rifaksimin, postupci za njihovu proizvodnju i njihova primjena u lijeäśenju vaginalnih infekcija | |
| MX2011005633A (es) | Formas de dosificacion solida de bendamustina. | |
| US20080318970A1 (en) | Treatment of Infectious Diseases | |
| US20170000762A1 (en) | Anti-microbial composition | |
| HRP20221381T1 (hr) | C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta | |
| EP2329819B1 (en) | Pharmaceutical composition for use in treating sexually transmitted infections | |
| US20230248745A1 (en) | Silver enhanced cannabinoid antibiotics | |
| EP2678015B1 (en) | Use of nifuratel to treat infections caused by clostridium species | |
| RU2014124118A (ru) | Фармацевтические препараты, включающие аторвастатин и глимепирид | |
| ES2280150T1 (es) | Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma. | |
| CN103505459B (zh) | 利奈唑胺药物组合物 | |
| DK2648704T3 (en) | Antimicrobial composition | |
| PE20220381A1 (es) | Formulacion de tableta vaginal | |
| WO2018142359A1 (en) | Composition comprising immediate release and extended release capecitabine | |
| AU2013254941A1 (en) | Compositions of stable tiacumicins |